{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:00:23Z","timestamp":1740150023067,"version":"3.37.3"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100004366","name":"Student Research Committee of Tabriz University of Medical Sciences, Tabriz, Iran","doi-asserted-by":"publisher","award":["61047"],"award-info":[{"award-number":["61047"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The Enhancer of Zeste Homolog 2 (EZH2) is a subunit of the polycomb repressive\ncomplex 2 that silences the gene transcription via H3K27me3. Previous studies have shown that EZH2 has an\nimportant role in the induction of the resistance against the Tumor necrosis factor-Related Apoptosis-Inducing\nLigand (TRAIL)-Induced Apoptosis (TIA) in some leukemia cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of this study was to determine the effect of silencing EZH2 gene expression using RNA\ninterference on the expression of death receptors 4 and 5 (DR4\/5), Preferentially expressed Antigen in Melanoma\n(PRAME), and TRAIL human lymphoid leukemia MOLT-4 cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Quantitative RT-PCR was used to detect the EZH2 expression and other candidate genes following\nthe siRNA knockdown in MOLT-4 cells. The toxicity of the EZH2 siRNA was evaluated using Annexin V\/PI\nassay following the transfection of the cells by 80 pM EZH2 siRNA at 48 hours.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Based on the flow-cytometry results, the EZH2 siRNA had no toxic effects on MOLT-4 cells. Also, the\nEZH2 inhibition increased the expression of DR4\/5 but reduced the PRAME gene expression at the mRNA\nlevels. Moreover, the EZH2 silencing could not change the TRAIL mRNA in the transfected cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Our results revealed that the down-regulation of EZH2 in MOLT-4 cells was able to affect the\nexpression of important genes involved in the induction of resistance against TIA. Hence, we suggest that the\nsilencing of EZH2 using RNA interference can be an effective and safe approach to help defeat the MOLT-4\ncell resistance against TIA.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200130091955","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T14:24:21Z","timestamp":1580394261000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-6845","authenticated-orcid":true,"given":"Adel","family":"Naimi","sequence":"first","affiliation":[{"name":"Cellular and Molecular Research Center, Sabzevar University of Medical Science, Sabzevar, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Safaei","sequence":"additional","affiliation":[{"name":"Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atefeh","family":"Entezari","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Solali","sequence":"additional","affiliation":[{"name":"Department of Immunology, Division of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hassanzadeh","sequence":"additional","affiliation":[{"name":"Department of Immunology, Division of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cppeds.2016.08.004","volume":"46","author":"Whitehead T.P.","year":"2016","unstructured":"Whitehead T.P.; Metayer C.; Wiemels J.L.; Singer A.W.; Miller M.D.; Childhood leukemia and primary prevention. Curr Probl Pediatr Adolesc Health Care 2016,46(10),317-352","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2017.36","volume":"31","author":"Reckel S.","year":"2017","unstructured":"Reckel S.; Hamelin R.; Georgeon S.; Armand F.; Jolliet Q.; Chiappe D.; Moniatte M.; Hantschel O.; Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia 2017,31(7),1502-1512","journal-title":"Leukemia"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ajh.25338","volume":"94","author":"Short N.J.","year":"2019","unstructured":"Short N.J.; Jabbour E.; Albitar M.; de Lima M.; Gore L.; Jorgensen J.; Logan A.C.; Park J.; Ravandi F.; Shah B.; Radich J.; Kantarjian H.; Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol 2019,94(2),257-265","journal-title":"Am J Hematol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel S.","year":"2019","unstructured":"Giebel S.; Marks D.I.; Boissel N.; Baron F.; Chiaretti S.; Ciceri F.; Cornelissen J.J.; Doubek M.; Esteve J.; Fielding A.; Foa R.; Gorin N.C.; Gokbuget N.; Hallbook H.; Hoelzer D.; Paravichnikova E.; Ribera J.M.; Savani B.; Rijneveld A.W.; Schmid C.; Wartiovaara-Kautto U.; Mohty M.; Nagler A.; Dombret H.; Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2019,54(6),798-809","journal-title":"Bone Marrow Transplant"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/2278-330X.187591","volume":"5","author":"Arora R.S.","year":"2016","unstructured":"Arora R.S.; Arora B.; Acute leukemia in children: A review of the current Indian data. South Asian J Cancer 2016,5(3),155-160","journal-title":"South Asian J Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"Terwilliger T.","year":"2017","unstructured":"Terwilliger T.; Abdul-Hay M.; Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 2017,7(6),e577-e577","journal-title":"Blood Cancer J"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011960.pub2","volume":"8","author":"K\u00fcley-Bagheri Y.","year":"2018","unstructured":"K\u00fcley-Bagheri Y.; Kreuzer K.A.; Monsef I.; L\u00fcbbert M.; Skoetz N.; Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)). Cochrane Database Syst Rev 2018,8","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.blre.2015.01.001","volume":"29","author":"Mei L.","year":"2015","unstructured":"Mei L.; Ontiveros E.P.; Griffiths E.A.; Thompson J.E.; Wang E.S.; Wetzler M.; Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev 2015,29(4),243-249","journal-title":"Blood Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"Cornelissen J.J.","year":"2016","unstructured":"Cornelissen J.J.; Blaise D.; Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016,127(1),62-70","journal-title":"Blood"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e0127790","DOI":"10.1371\/journal.pone.0127790","volume":"10","author":"Su M.","year":"2015","unstructured":"Su M.; Alonso S.; Jones J.W.; Yu J.; Kane M.A.; Jones R.J.; Ghiaur G.; All-Trans retinoic acid activity in acute myeloid leukemia: Role of cytochrome P450 enzyme expression by the microenvironment. PLoS One 2015,10(6),e0127790-e0127790","journal-title":"PLoS One"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"11427","DOI":"10.1523\/JNEUROSCI.2492-16.2016","volume":"36","author":"Cholewa-Waclaw J.","year":"2016","unstructured":"Cholewa-Waclaw J.; Bird A.; von Schimmelmann M.; Schaefer A.; Yu H.; Song H.; Madabhushi R.; Tsai L-H.; The role of epigenetic mechanisms in the regulation of gene expression in the nervous system. J Neurosci 2016,36(45),11427-11434","journal-title":"J Neurosci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.arplant.58.032806.103835","volume":"58","author":"Chen Z.J.","year":"2007","unstructured":"Chen Z.J.; Genetic and epigenetic mechanisms for gene expression and phenotypic variation in plant polyploids. Annu Rev Plant Biol 2007,58,377-406","journal-title":"Annu Rev Plant Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"Sharma S.","year":"2010","unstructured":"Sharma S.; Kelly T.K.; Jones P.A.; Epigenetics in cancer. Carcinogenesis 2010,31(1),27-36","journal-title":"Carcinogenesis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-med-111314-035900","volume":"67","author":"Ahuja N.","year":"2016","unstructured":"Ahuja N.; Sharma A.R.; Baylin S.B.; Epigenetic therapeutics: A new weapon in the war against cancer. Annu Rev Med 2016,67,73-89","journal-title":"Annu Rev Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/embor.2009.102","volume":"10","author":"Shaw T.","year":"2009","unstructured":"Shaw T.; Martin P.; Epigenetic reprogramming during wound healing: loss of polycomb-mediated silencing may enable upregulation of repair genes. EMBO Rep 2009,10(8),881-886","journal-title":"EMBO Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11248-016-9993-x","volume":"26","author":"Koppens M.A.","year":"2017","unstructured":"Koppens M.A.; Tanger E.; Nacerddine K.; Westerman B.; Song J.Y.; van Lohuizen M.; A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2. Transgenic Res 2017,26(2),187-196","journal-title":"Transgenic Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2011.58","volume":"25","author":"Abdel-Wahab O.","year":"2011","unstructured":"Abdel-Wahab O.; Pardanani A.; Patel J.; Wadleigh M.; Lasho T.; Heguy A.; Beran M.; Gilliland D.G.; Levine R.L.; Tefferi A.; Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011,25(7),1200-1202","journal-title":"Leukemia"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"Cao R.","year":"2002","unstructured":"Cao R.; Wang L.; Wang H.; Xia L.; Erdjument-Bromage H.; Tempst P.; Jones R.S.; Zhang Y.; Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002,298(5595),1039-1043","journal-title":"Science"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.biopha.2017.12.059","volume":"98","author":"Safaei S.","year":"2018","unstructured":"Safaei S.; Baradaran B.; Hagh M.F.; Alivand M.R.; Talebi M.; Gharibi T.; Solali S.; Double sword role of EZH2 in leukemia. Biomed Pharmacother 2018,98,626-635","journal-title":"Biomed Pharmacother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ccell.2018.01.006","volume":"33","author":"Booth C.A.G.","year":"2018","unstructured":"Booth C.A.G.; Barkas N.; Neo W.H.; Boukarabila H.; Soilleux E.J.; Giotopoulos G.; Farnoud N.; Giustacchini A.; Ashley N.; Carrelha J.; Jamieson L.; Atkinson D.; Bouriez-Jones T.; Prinjha R.K.; Milne T.A.; Teachey D.T.; Papaemmanuil E.; Huntly B.J.P.; Jacobsen S.E.W.; Mead A.J.; Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors. Cancer Cell 2018,33(2),274-291","journal-title":"Cancer Cell"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","volume":"8","author":"Patnaik M.M.","year":"2018","unstructured":"Patnaik M.M.; Vallapureddy R.; Lasho T.L.; Hoversten K.P.; Finke C.M.; Ketterling R.; Hanson C.; Gangat N.; Tefferi A.; EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer J 2018,8(1),12","journal-title":"Blood Cancer J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3892\/or.2018.6272","volume":"39","author":"Brunetti G.","year":"2018","unstructured":"Brunetti G.; Di Benedetto A.; Posa F.; Colaianni G.; Faienza M.F.; Ballini A.; Colucci S.; Passeri G.; Lo Muzio L.; Grano M.; Mori G.; High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. Oncol Rep 2018,39(4),2031-2039","journal-title":"Oncol Rep"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"13233","DOI":"10.1002\/jcp.27995","volume":"234","author":"Naimi A.","year":"2019","unstructured":"Naimi A.; Entezari A.; Hagh M.F.; Hassanzadeh A.; Saraei R.; Solali S.; Quercetin sensitizes human myeloid leukemia KG-1 cells against TRAIL-induced apoptosis. J Cell Physiol 2019,234(8),13233-13241","journal-title":"J Cell Physiol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.biopha.2018.08.065","volume":"107","author":"Saraei R.","year":"2018","unstructured":"Saraei R.; Soleimani M.; Movassaghpour Akbari A.A.; Farshdousti Hagh M.; Hassanzadeh A.; Solali S.; The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Biomed Pharmacother 2018,107,1010-1019","journal-title":"Biomed Pharmacother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1517\/14728222.11.10.1299","volume":"11","author":"M\u00e9rino D.","year":"2007","unstructured":"M\u00e9rino D.; Lalaoui N.; Morizot A.; Solary E.; Micheau O.; TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007,11(10),1299-1314","journal-title":"Expert Opin Ther Targets"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1002\/jcp.26585","volume":"233","author":"Hassanzadeh A.","year":"2018","unstructured":"Hassanzadeh A.; Farshdousti Hagh M.; Alivand M.R.; Akbari A.A.M.; Shams Asenjan K.; Saraei R.; Solali S.; Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL. J Cell Physiol 2018,233(10),6470-6485","journal-title":"J Cell Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.3892\/or.2017.5627","volume":"37","author":"Kong X.","year":"2017","unstructured":"Kong X.; Luo J.; Xu T.; Zhou Y.; Pan Z.; Xie Y.; Zhao L.; Lu Y.; Han X.; Li Z.; Liu L.; Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi\u20111 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP. Oncol Rep 2017,37(6),3423-3432","journal-title":"Oncol Rep"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.biopha.2017.12.082","volume":"98","author":"Naimi A.","year":"2018","unstructured":"Naimi A.; Movassaghpour A.A.; Hagh M.F.; Talebi M.; Entezari A.; Jadidi-Niaragh F.; Solali S.; TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies. Biomed Pharmacother 2018,98,566-576","journal-title":"Biomed Pharmacother"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","volume":"22","author":"Rathore R.","year":"2017","unstructured":"Rathore R.; McCallum J.E.; Varghese E.; Florea A.M.; Busselberg D.; Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis: Int J Program Cell Death 2017,22(7),898-919","journal-title":"Apoptosis: Int J Program Cell Death"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/cdd.2017.40","volume":"24","author":"Haimovici A.","year":"2017","unstructured":"Haimovici A.; Humbert M.; Federzoni E.A.; Shan-Krauer D.; Brunner T.; Frese S.; Kaufmann T.; Torbett B.E.; Tschan M.P.; PU.1 supports TRAIL-induced cell death by inhibiting NF-\u03baB-mediated cell survival and inducing DR5 expression. Cell Death Differ 2017,24(5),866-877","journal-title":"Cell Death Differ"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc.2017.28","volume":"17","author":"von Karstedt S.","year":"2017","unstructured":"von Karstedt S.; Montinaro A.; Walczak H.; Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer 2017,17(6),352-366","journal-title":"Nat Rev Cancer"},{"key":"ref=32","first-page":"55","volume":"2","author":"Jazirehi A.R.","year":"2013","unstructured":"Jazirehi A.R.; Arle D.; Epigenetic regulation of the TRAIL\/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol 2013,2(1),55-74","journal-title":"Am J Clin Exp Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091558","volume":"9","author":"Fr\u00f6hlich L.F.","year":"2014","unstructured":"Fr\u00f6hlich L.F.; Mrakovcic M.; Smole C.; Lahiri P.; Zatloukal K.; Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells. PLoS One 2014,9(3)","journal-title":"PLoS One"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/onc.2010.409","volume":"30","author":"De Carvalho D.D.","year":"2011","unstructured":"De Carvalho D.D.; Binato R.; Pereira W.O.; Leroy J.M.; Colassanti M.D.; Proto-Siqueira R.; Bueno-Da-Silva A.E.; Zago M.A.; Zanichelli M.A.; Abdelhay E.; Castro F.A.; Jacysyn J.F.; Amarante-Mendes G.P.; BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2011,30(2),223-233","journal-title":"Oncogene"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1753-6561-7-S2-P10","volume":"7","author":"Mello B.P.","year":"2013","unstructured":"Mello B.P.; de Carvalho D.D.; Campos A.H.; Soares F.A.; Amarante-Mendes G.P.; Regulation of TRAIL expression by PRAME and EZH2 as potential therapeutic target against solid tumors. BMC Proc 2013,7(Suppl. 2),10-P10","journal-title":"BMC Proc"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.lrr.2016.09.001","volume":"6","author":"Medinger M.","year":"2016","unstructured":"Medinger M.; Lengerke C.; Passweg J.; Novel therapeutic options in Acute Myeloid Leukemia. Leuk Res Rep 2016,6,39-49","journal-title":"Leuk Res Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"Ludwig H.","year":"2018","unstructured":"Ludwig H.; Delforge M.; Facon T.; Einsele H.; Gay F.; Moreau P.; Avet-Loiseau H.; Boccadoro M.; Hajek R.; Mohty M.; Cavo M.; Dimopoulos M.A.; San-Miguel J.F.; Terpos E.; Zweegman S.; Garderet L.; Mateos M-V.; Cook G.; Leleu X.; Goldschmidt H.; Jackson G.; Kaiser M.; Weisel K.; van de Donk N.W.C.J.; Waage A.; Beksac M.; Mellqvist U.H.; Engelhardt M.; Caers J.; Driessen C.; Blad\u00e9 J.; Sonneveld P.; Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018,32(7),1542-1560","journal-title":"Leukemia"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/cdd.2015.174","volume":"23","author":"de Miguel D.","year":"2016","unstructured":"de Miguel D.; Lemke J.; Anel A.; Walczak H.; Martinez-Lostao L.; Onto better TRAILs for cancer treatment. Cell Death Differ 2016,23(5),733-747","journal-title":"Cell Death Differ"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.leukres.2010.12.032","volume":"35","author":"Chamuleau M.E.","year":"2011","unstructured":"Chamuleau M.E.; Ossenkoppele G.J.; van Rhenen A.; van Dreunen L.; Jirka S.M.; Zevenbergen A.; Schuurhuis G.J.; van de Loosdrecht A.A.; High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk Res 2011,35(6),741-749","journal-title":"Leuk Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/1878-0261.12146","volume":"12","author":"Zhou J.","year":"2018","unstructured":"Zhou J.; Lu X.; Tan T.Z.; Chng W.J.; X-linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to TRAIL and chemotherapy through potentiated induction of proapoptotic machinery. Mol Oncol 2018,12(1),33-47","journal-title":"Mol Oncol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1026131425204","volume":"8","author":"Hao X.S.","year":"2003","unstructured":"Hao X.S.; Hao J.H.; Liu F.T.; Newland A.C.; Jia L.; Potential mechanisms of leukemia cell resistance to TRAIL-induced apopotosis. Apoptosis: Int J Program Cell Death 2003,8(6),601-607","journal-title":"Apoptosis: Int J Program Cell Death"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/ijms19103187","volume":"19","author":"Lim E.J.","year":"2018","unstructured":"Lim E.J.; Yoon Y.J.; Heo J.; Lee T.H.; Kim Y-H.; Ciprofloxacin enhances TRAIL-induced apoptosis in lung cancer cells by upregulating the expression and protein stability of death receptors through CHOP expression. Int J Mol Sci 2018,19(10),3187","journal-title":"Int J Mol Sci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2018.10.159","volume":"508","author":"Park S.H.","year":"2019","unstructured":"Park S.H.; Kim J.L.; Jeong S.; Kim B.R.; Na Y.J.; Jo M.J.; Yun H.K.; Jeong Y.A.; Kim D.Y.; Kim B.G.; You S.; Oh S.C.; Lee D.H.; Codium fragile F2 sensitize colorectal cancer cells to TRAIL-induced apoptosis via c-FLIP ubiquitination. Biochem Biophys Res Commun 2019,508(1),1-8","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3858\/emm.2011.43.1.003","volume":"43","author":"Kang Y.J.","year":"2011","unstructured":"Kang Y.J.; Kim I.Y.; Kim E.H.; Yoon M.J.; Kim S.U.; Kwon T.K.; Choi K.S.; Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5. Exp Mol Med 2011,43(1),24-34","journal-title":"Exp Mol Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/MCB.20.1.205-212.2000","volume":"20","author":"Gibson S.B.","year":"2000","unstructured":"Gibson S.B.; Oyer R.; Spalding A.C.; Anderson S.M.; Johnson G.L.; Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000,20(1),205-212","journal-title":"Mol Cell Biol"},{"key":"ref=46","first-page":"1121","volume":"45","author":"Zhu H.","year":"2018","unstructured":"Zhu H.; Wang J.; Yin J.; Lu B.; Yang Q.; Wan Y.; Jia C.; Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of P53 mediated pathway. Cell. Physiol. Biochem.: Int. J. Experim. Cell. Physiol. Biochem, Pharmaco 2018,45(3),1121-1135","journal-title":"Biochem, Pharmaco"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood.V122.21.4425.4425","volume":"122","author":"Mathur R.","year":"2013","unstructured":"Mathur R.; Sehgal L.; Berkova Z.; Samaniego F.; Histone 3 Methyltransferase (EZH2) inhibition enhances TRAIL-induced apoptosis in mantle cell lymphoma cells by accelerated cFLIP degradation. Blood 2013,122(21),4425-4425","journal-title":"Blood"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"e0117994","DOI":"10.1371\/journal.pone.0117994","volume":"10","author":"Braun F.K.","year":"2015","unstructured":"Braun F.K.; Mathur R.; Sehgal L.; Wilkie-Grantham R.; Chandra J.; Berkova Z.; Samaniego F.; Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis. PLoS One 2015,10(3),e0117994-e0117994","journal-title":"PLoS One"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2013-12-544106","volume":"124","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Kinkel S.; Maksimovic J.; Bandala-Sanchez E.; Tanzer M.C.; Naselli G.; Zhang J-G.; Zhan Y.; Lew A.M.; Silke J.; Oshlack A.; Blewitt M.E.; Harrison L.C.; The polycomb repressive complex 2 governs life and death of peripheral T cells. Blood 2014,124(5),737-749","journal-title":"Blood"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T11:50:30Z","timestamp":1596023430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178839\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200130091955","relation":{},"ISSN":["1871-5206"],"issn-type":[{"type":"print","value":"1871-5206"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}